Respiratory syncytial virus infection in elderly and high-risk adults
- PMID: 15858184
- DOI: 10.1056/NEJMoa043951
Respiratory syncytial virus infection in elderly and high-risk adults
Abstract
Background: Respiratory syncytial virus (RSV) is an increasingly recognized cause of illness in adults. Data on the epidemiology and clinical effects in community-dwelling elderly persons and high-risk adults can help in assessing the need for vaccine development.
Methods: During four consecutive winters, we evaluated all respiratory illnesses in prospective cohorts of healthy elderly patients (> or =65 years of age) and high-risk adults (those with chronic heart or lung disease) and in patients hospitalized with acute cardiopulmonary conditions. RSV infection and influenza A were diagnosed on the basis of culture, reverse-transcriptase polymerase chain reaction, and serologic studies.
Results: A total of 608 healthy elderly patients and 540 high-risk adults were enrolled in prospective surveillance, and 1388 hospitalized patients were enrolled. A total of 2514 illnesses were evaluated. RSV infection was identified in 102 patients in the prospective cohorts and 142 hospitalized patients, and influenza A was diagnosed in 44 patients in the prospective cohorts and 154 hospitalized patients. RSV infection developed annually in 3 to 7 percent of healthy elderly patients and in 4 to 10 percent of high-risk adults. Among healthy elderly patients, RSV infection generated fewer office visits than influenza; however, the use of health care services by high-risk adults was similar in the two groups. In the hospitalized cohort, RSV infection and influenza A resulted in similar lengths of stay, rates of use of intensive care (15 percent and 12 percent, respectively), and mortality (8 percent and 7 percent, respectively). On the basis of the diagnostic codes of the International Classification of Diseases, 9th Revision, Clinical Modification at discharge, RSV infection accounted for 10.6 percent of hospitalizations for pneumonia, 11.4 percent for chronic obstructive pulmonary disease, 5.4 percent for congestive heart failure, and 7.2 percent for asthma.
Conclusions: RSV infection is an important illness in elderly and high-risk adults, with a disease burden similar to that of nonpandemic influenza A in a population in which the prevalence of vaccination for influenza is high. An effective RSV vaccine may offer benefits for these adults.
Copyright 2005 Massachusetts Medical Society.
Comment in
-
RSV infection--not for kids only.N Engl J Med. 2005 Apr 28;352(17):1810-2. doi: 10.1056/NEJMe058036. N Engl J Med. 2005. PMID: 15858191 No abstract available.
-
Respiratory syncytial virus infection in elderly adults.N Engl J Med. 2005 Jul 28;353(4):422-3; author reply 422-3. doi: 10.1056/NEJM200507283530422. N Engl J Med. 2005. PMID: 16049217 No abstract available.
-
Respiratory syncytial virus infection in elderly adults.N Engl J Med. 2005 Jul 28;353(4):422-3; author reply 422-3. N Engl J Med. 2005. PMID: 16050055 No abstract available.
Similar articles
-
Influenza and respiratory syncytial virus in the elderly.Expert Rev Vaccines. 2008 Mar;7(2):249-58. doi: 10.1586/14760584.7.2.249. Expert Rev Vaccines. 2008. PMID: 18324893 Review.
-
Risk factors for severe respiratory syncytial virus infection in elderly persons.J Infect Dis. 2004 Jan 15;189(2):233-8. doi: 10.1086/380907. Epub 2004 Jan 9. J Infect Dis. 2004. PMID: 14722887
-
Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease.Am J Respir Crit Care Med. 1999 Sep;160(3):791-5. doi: 10.1164/ajrccm.160.3.9901004. Am J Respir Crit Care Med. 1999. PMID: 10471598
-
Respiratory syncytial virus infections in previously healthy working adults.Clin Infect Dis. 2001 Sep 15;33(6):792-6. doi: 10.1086/322657. Epub 2001 Aug 21. Clin Infect Dis. 2001. PMID: 11512084
-
Respiratory syncytial virus infection in adults.Semin Respir Crit Care Med. 2007 Apr;28(2):171-81. doi: 10.1055/s-2007-976489. Semin Respir Crit Care Med. 2007. PMID: 17458771 Review.
Cited by
-
Epidemiological characteristics of five non-COVID respiratory viruses among 37,139 all-age patients during 2018 - 2023 in Weifang, China: a cross-sectional study.BMC Infect Dis. 2024 Nov 20;24(1):1324. doi: 10.1186/s12879-024-10212-7. BMC Infect Dis. 2024. PMID: 39567889 Free PMC article.
-
Hospitalization Following Outpatient Diagnosis of Respiratory Syncytial Virus in Adults.JAMA Netw Open. 2024 Nov 4;7(11):e2446010. doi: 10.1001/jamanetworkopen.2024.46010. JAMA Netw Open. 2024. PMID: 39560940 Free PMC article.
-
Health Technology Assessment del vaccino ricombinante adiuvato contro il virus respiratorio sinciziale (Arexvy®).J Prev Med Hyg. 2024 Jun 30;65(2 Suppl 1):E1-E159. doi: 10.15167/2421-4248/jpmh2024.65.2s1. eCollection 2024 Sep. J Prev Med Hyg. 2024. PMID: 39554593 Free PMC article. Italian. No abstract available.
-
Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus.Nat Commun. 2024 Nov 16;15(1):9939. doi: 10.1038/s41467-024-54287-x. Nat Commun. 2024. PMID: 39550381 Free PMC article.
-
Leveraging Real-World Evidence to Define Severe RSV Lower Respiratory Tract Disease in Adults.Infect Dis Ther. 2024 Nov 16. doi: 10.1007/s40121-024-01072-4. Online ahead of print. Infect Dis Ther. 2024. PMID: 39549152
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical